tiprankstipranks
Instil Bio resumes clinical trial of ITIL-306 in lung, ovarian, renal cancer
The Fly

Instil Bio resumes clinical trial of ITIL-306 in lung, ovarian, renal cancer

Instil Bio announced the resumption of its Phase 1 clinical trial of ITIL-306 for the treatment of non-small cell lung cancer, ovarian cancer, and renal cell carcinoma. With the resumption of the ITIL-306 Phase 1 study, the Company expects to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023. The trial was resumed after the implementation of additional quality safeguards designed to further protect the manufacturing process from potential contaminants.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on TIL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles